Towercrest Capital Management Acquires New Position in Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB)

Towercrest Capital Management bought a new position in shares of Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,886,715 shares of the company’s stock, valued at approximately $299,000. Towercrest Capital Management owned 0.75% of Matinas BioPharma at the end of the most recent quarter.

Separately, Private Advisor Group LLC raised its stake in shares of Matinas BioPharma by 31.1% during the 4th quarter. Private Advisor Group LLC now owns 337,330 shares of the company’s stock worth $73,000 after buying an additional 80,000 shares during the last quarter. 11.77% of the stock is owned by institutional investors and hedge funds.

Matinas BioPharma Price Performance

Shares of MTNB traded down $0.19 during mid-day trading on Friday, reaching $3.45. 93,224 shares of the company’s stock were exchanged, compared to its average volume of 28,284. Matinas BioPharma Holdings, Inc. has a 52-week low of $3.28 and a 52-week high of $44.50. The stock has a market cap of $865.33 million, a price-to-earnings ratio of -28.75 and a beta of 1.70.

Matinas BioPharma (NYSEAMERICAN:MTNB) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($0.02) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.02).

About Matinas BioPharma

Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.